Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Overactive Bladder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    116 result(s) found for: Overactive Bladder. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2006-003730-15 Sponsor Protocol Number: D3601113 Start Date*: 2007-01-09
    Sponsor Name:Dainippon Sumitomo Pharma Europe Ltd.
    Full Title: A 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and ...
    Medical condition: Overactive Bladder Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed) LT (Completed) LV (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005145-11 Sponsor Protocol Number: BAY 38-9456 / 12392 Start Date*: 2007-07-27
    Sponsor Name:Bayer Healthcare AG
    Full Title: Randomized, double-blind, placebo-controlled, parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity).
    Medical condition: Overactive bladder (detrusor overactivity)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PT (Completed) ES (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005344-15 Sponsor Protocol Number: BOTC3-OAB-01 Start Date*: 2013-03-25
    Sponsor Name:Adyton, s.r.o.
    Full Title: A Double Blind Study Aiming To Evaluate The Efficacy Of Bladder Instillation With Botulinum Toxin (200U) + TC-3 Gel In Comparison To Instillation With Botulinum Toxin (200U) + TC-3 Gel + DMSO, To D...
    Medical condition: Overactive bladder (OAB) syndrome (in women), as defined by the International Continence Society (ICS): severe urgency with or without urge urinary incontinence, usually accompanied with increased ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004452-13 Sponsor Protocol Number: A6121127 Start Date*: 2005-12-16
    Sponsor Name:Pfizer Inc.
    Full Title: A Randomized, Double Blind, Placebo Controlled Detrol La "Add-On" To Alpha-Blocker Study in men with persistent Overactive Bladder symptoms of urinary frequency and urgency with/without urgency inc...
    Medical condition: Overactive Bladder in Men
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020853 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) ES (Completed) DK (Completed) GB (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001334-40 Sponsor Protocol Number: PSD506-OAB-005 Start Date*: 2006-09-29
    Sponsor Name:PLETHORA SOLUTIONS LIMITED
    Full Title: A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)
    Medical condition: overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002533-18 Sponsor Protocol Number: 4618-008-10 Start Date*: 2012-06-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: 52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001068-36 Sponsor Protocol Number: R03465 Start Date*: 2014-10-22
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)
    Medical condition: Idiopathic Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002575-34 Sponsor Protocol Number: 19733 Start Date*: 2020-06-10
    Sponsor Name:Bayer AG
    Full Title: A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over ...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) PL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017939-18 Sponsor Protocol Number: 08/0316 Start Date*: 2010-12-15
    Sponsor Name:University College London
    Full Title: A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated w...
    Medical condition: Chronic urinary tract infection.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024179-18 Sponsor Protocol Number: A0221094 Start Date*: 2011-05-31
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DE (Completed) CZ (Completed) FI (Completed) GR (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006070-22 Sponsor Protocol Number: A0221007 Start Date*: 2007-03-16
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS
    Medical condition: Overactive bladder (OAB) is a symptom complex defined by the International Continence Society (ICS) as the symptoms of urgency, with or without urgency incontinence, usually with frequency and noct...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002256-17 Sponsor Protocol Number: 178-CL-044 Start Date*: 2006-01-19
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON)
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) SE (Completed) BE (Completed) HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007087-17 Sponsor Protocol Number: A0221045 Start Date*: 2008-06-13
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
    Full Title: A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence (Some patients will also have urgency urinary incontinence (UUI)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) BE (Completed) SK (Completed) AT (Completed) DE (Completed) DK (Completed) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004249-33 Sponsor Protocol Number: A8881001 Start Date*: 2005-12-14
    Sponsor Name:Pfizer Limited
    Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ...
    Medical condition: Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022121-15 Sponsor Protocol Number: 4618-008 Start Date*: 2011-04-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) AT (Completed) NO (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000700-26 Sponsor Protocol Number: 178-CL-203 Start Date*: 2015-09-23
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of a...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10012547 Detrusor hyperreflexia LLT
    19.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006538-33 Sponsor Protocol Number: ONO-8539POE004 Start Date*: 2009-03-23
    Sponsor Name:Ono Pharmaceutical Co. Ltd.
    Full Title: A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BL...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000340-15 Sponsor Protocol Number: 178-CL-202 Start Date*: 2014-07-11
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single ascending dose Phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron OCAS tablets in pediatric subjects from 5 to less than 18 year...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10012547 Detrusor hyperreflexia LLT
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NO (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022611-19 Sponsor Protocol Number: XEN-D0501-CL-03 Start Date*: 2011-01-07
    Sponsor Name:Xention Limited
    Full Title: A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bla...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 21:18:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA